Darolutamide Combination Cuts Metastasis or Death Risk 58% in High-Risk Prostate Cancer

Orion said late-breaking data show darolutamide plus ADT and radiation therapy reduced the risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence. The data were to be presented on Oct. 24.